Sandbox vidit: Difference between revisions
Jump to navigation
Jump to search
| Line 2: | Line 2: | ||
<table class="wikitable"> | <table class="wikitable"> | ||
<tr class="v-firstrow"><th>Drug</th><th> | <tr class="v-firstrow"><th>Drug</th><th>Class of Recommendation/Level of Evidence</th><th> Dosage </th></tr> | ||
<tr><td>Dofetilide</td><td> | <tr><td>Dofetilide</td><td>I A</td><td><table class="wikitable"> | ||
<tr class="v-firstrow"><th>Creatinine clearance(ml/min)</th><th>Dose (mg)</th></tr> | <tr class="v-firstrow"><th>Creatinine clearance(ml/min)</th><th>Dose (mg)</th></tr> | ||
<tr><td> >60</td><td>500</td></tr> | <tr><td> >60</td><td>500</td></tr> | ||
| Line 10: | Line 10: | ||
<tr><td> <20</td><td>Contraindicated</td></tr> | <tr><td> <20</td><td>Contraindicated</td></tr> | ||
</table></td></tr> | </table></td></tr> | ||
<tr><td>Flecainide</td><td> | <tr><td>Flecainide</td><td> I A</td><td>'''Oral:''' 200 to 300 mg <br> | ||
'''Intravenous:''' 1.5 to 3.0 mg/kg over 10 to 20 min</td></tr> | '''Intravenous:''' 1.5 to 3.0 mg/kg over 10 to 20 min</td></tr> | ||
<tr><td>Ibutilide</td><td> | <tr><td>Ibutilide</td><td>I A </td><td>1 mg over 10 min; repeat 1 mg when necessary</td></tr> | ||
<tr><td>Propafenone</td><td> | <tr><td>Propafenone</td><td>I A</td><td>'''Oral:''' 600 mg <br> | ||
'''Intravenous:''' 1.5 to 2.0 mg/kg over 10 to 20 min</td></tr> | '''Intravenous:''' 1.5 to 2.0 mg/kg over 10 to 20 min</td></tr> | ||
<tr><td>Amiodarone</td><td> | <tr><td>Amiodarone</td><td>IIa A</td><td>'''Oral:''' | ||
: Inpatient: 1.2 to 1.8 g per day in divided dose until 10 g total <br> then 200 to 400 mg per day maintenance or 30 mg/kg as single dose <br> | : Inpatient: 1.2 to 1.8 g per day in divided dose until 10 g total <br> then 200 to 400 mg per day maintenance or 30 mg/kg as single dose <br> | ||
: Outpatient: 600 to 800 mg per day divided dose until 10 g total <br> then 200 to 400 mg per day maintenance. <br> | : Outpatient: 600 to 800 mg per day divided dose until 10 g total <br> then 200 to 400 mg per day maintenance. <br> | ||
Revision as of 16:45, 3 March 2014
Cardioversion upto7 Days
| Drug | Class of Recommendation/Level of Evidence | Dosage | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dofetilide | I A |
| ||||||||||
| Flecainide | I A | Oral: 200 to 300 mg Intravenous: 1.5 to 3.0 mg/kg over 10 to 20 min | ||||||||||
| Ibutilide | I A | 1 mg over 10 min; repeat 1 mg when necessary | ||||||||||
| Propafenone | I A | Oral: 600 mg Intravenous: 1.5 to 2.0 mg/kg over 10 to 20 min | ||||||||||
| Amiodarone | IIa A | Oral:
Intravenous:
|
Cardioversion after 7 Days
| Drug | Route | Dosage | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dofetilide | Oral |
| ||||||||||
| Amiodarone | Oral or Intravenous | Oral:
Intravenous:
| ||||||||||
| Ibutilide | Intravenous | 1 mg over 10 min; repeat 1 mg when necessary |
Drugs which enhance the efficacy of cardioversion when given prior to the procedure: (Level of recommendation: IIa B)
- Amiodarone
- Flecainide
- Ibutilide
- Propafenone
- Sotalol
Drug Dosages for Maintenance of Sinus Rhythm
Following table summarizes the list of most commonly used drugs and their dosages for maintenance of sinus rhythm:
| Drug | Dose |
|---|---|
| Amiodarone | 100 to 400 mg |
| Disopyramide | 400 to 750 mg |
| Dofetilide | 5000 to 1000 mcg |
| Flecainide | 200 to 300 mg |
| Procainamide | 1000 to 4000 mg |
| Propafenone | 450 to 900 mg |
| Quinidine | 600 to 1500 mg |
| Sotalol | 160 to 320 mg |